Placebo/Galantamine (Reminyl®) — Competitive Intelligence Brief

Placebo/Galantamine (Reminyl®) (Placebo/Galantamine (Reminyl®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase inhibitor. Area: Neurology.

marketed Acetylcholinesterase inhibitor Acetylcholinesterase; nicotinic acetylcholine receptors Neurology Small molecule

Target snapshot

Placebo/Galantamine (Reminyl®) (Placebo/Galantamine (Reminyl®)) — Ludwig-Maximilians - University of Munich. Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, improving cognitive function in Alzheimer's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo/Galantamine (Reminyl®) TARGET	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Galantamine (Reminyl)	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
Extended-release galantamine hydrobromide	Extended-release galantamine hydrobromide	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Cholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Donepezil (Aricept)	Donepezil (Aricept)	University of Virginia	marketed	Acetylcholinesterase Inhibitor	Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon
Propranolol+pyridostigmine	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase
Huperzine A Injection	Huperzine A Injection	Second Affiliated Hospital of Wenzhou Medical University	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholinesterase inhibitor class)

1. Eisai Inc. · 2 drugs in this class
2. Ludwig-Maximilians - University of Munich · 1 drug in this class
3. Neurognostics · 1 drug in this class
4. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
5. Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
6. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
7. Shanghai Mental Health Center · 1 drug in this class